36
Participants
Start Date
July 31, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
March 31, 2014
PF-03446962
PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
National Cancer Center Hospital East, Kashiwa
Seoul National University Hospital/Department of Internal Medicine, Seoul
Lead Sponsor
Pfizer
INDUSTRY